Jul 9, 2013, 2:00 PM, Posted by Catherine Arnst
The New Yorker recently ran an excellent article by Jerome Groopman MD, Before Night Falls, about efforts to find a drug that can delay or even stop the onset of Alzheimer’s. What struck me most about this thorough piece of reporting, however, is that it covers much the same ground as a feature I wrote for Businessweek—in 2007. Despite the huge amount of money and other resources devoted to Alzheimer’s research, the quest for an effective treatment has moved forward by mere fractions in the past six years.
Almost every drug I wrote about in 2007 has since failed, which means it will be at least a decade, and probably far longer, before an effective treatment wins regulatory approval. Meanwhile, the Alzheimer’s Association recently reported that one in three seniors will die with Alzheimer’s or another form of dementia in the U.S. this year, and 5.2 million people are currently living with Alzheimer’s. By 2025, the number of people living with the disease will likely reach 7.1 million. So while we’re waiting for a cure, the medical community should also be developing better methods for caring for the millions of patients who are suffering right now.